ClinicalTrials.gg
WithdrawnNCT07006805Updated Jun 25, 2026

RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

A Phase 1/2 interventional study of CABA-201 in Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS) and Multiple Sclerosis - Relapsing Remitting, sponsored by Cabaletta Bio. Withdrawn. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Cabaletta Bio · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
The study was withdrawn prior to site activation and before enrollment of any participants due to sponsor decision to reprioritize the development portfolio.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

RESET-MS: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Participants with Multiple Sclerosis

Read the detailed description

This is a Phase 1/2, open-label study designed to evaluate the safety, tolerability, and efficacy of different doses of CABA-201 in adult participants with MS to determine an appropriate dose for future studies. Any participant who receives CABA-201 will be followed after infusion for 156 weeks. Two cohorts of participants will be studied based upon their MS diagnosis.

  • Relapsing MS Cohort (RMS Cohort): Participants with active relapsing MS, including relapsing remitting MS (RRMS) and relapsing secondary progressive MS (SPMS) that is treatment-resistant
  • Progressive MS Cohort (PMS Cohort): Participants with worsening progressive MS, including primary progressive MS (PPMS) or non-relapsing SPMS that is treatment-resistant

The study will consist of 2 parts: Part A (dose escalation) and Part B (dose expansion).

02

Conditions studied

  • Relapsing Multiple Sclerosis (RMS)
  • Progressive Multiple Sclerosis (PMS)
  • Multiple Sclerosis - Relapsing Remitting
  • Multiple Sclerosis
  • Multiple Sclerosis (Relapsing Remitting)
  • Multiple Sclerosis (MS) - Relapsing-remitting
  • Progressive Multiple Sclerosis

Keywords

  • CABA-201
  • Rese-cel
  • autoimmune disease
  • anti-CD19 CAR-T therapy
  • cellular therapy
  • Multiple Sclerosis
  • Relapsing MS
  • RRMS
  • Progressive MS
  • PPMS
  • SPMS
  • Neurology
  • Resecabtagene autoleucel
03

In context

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Lead sponsor

Cabaletta Bio is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include the following:

  • Able to provide .
  • Age ≥18 and ≤60 years of age.
  • Diagnosis of MS per the revised 2017 McDonald criteria (Thompson et al, 2018).
  • For participants with relapsing forms of MS only (RMS Cohort):

    1. Moderate degree of previously accumulated disability as measured by the Expanded Disability Status Scale (EDSS)
    2. Documentation of clinical relapse or a positive historical gadolinium (Gd)-enhancing magnetic resonance imaging (MRI) scan prior to Screening
    3. Prior treatment with a high-efficacy therapy or prior treatment failure of oral therapies
  • For participants with progressive forms of MS only (PMS cohort):

    1. Moderate Disability as measured by EDSS
    2. Presence of abnormal function on protocol specified EDSS Functional Systems Scale
    3. Objective worsening of disease prior to Screening while on standard of care therapy
  • Clinical stability by vital signs assessment at the time of screening

Exclusion criteria

Exclusion Criteria

The main exclusion criteria include the following:

  • History of fulminant MS
  • concomitant central nervous system pathologies which, in the Investigator's judgement, may confound the ability to interpret study results or complicate identification or evaluation of neurotoxicity, including but not limited to:

    1. Any history of seizure disorder, even if well-controlled on antiepileptics
    2. History of progressive multifocal leukoencephalopathy
  • Active, inflammatory disorder other than MS requiring immunomodulatory therapies

    a. Positive (HIV), virus (HCV) antibody, or surface antigen test, or evidence of active or chronic tuberculosis (TB) at Screening or other chronic viral infections as described in the protocol

  • Use of the following therapies:

    1. Any prior or concurrent exposure to mitoxantrone, alemtuzumab, total lymphoid irradiation
    2. Cladribine within 1 year of Screening
    3. Any agent within 4 weeks or 5 half-lives of Screening, whichever is longer
    4. Other pre-specified Disease-Modifying Therapies be discontinued by the time of pre-conditioning or earlier as described in the protocol
  • Known or a history of malignancy
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, or concomitant neurological disease, including severe (requiring medical intervention) and uncontrolled infections
  • Chronic pulmonary disease
  • Impaired cardiac function or clinically significant cardiac disease
  • Prior engineered T cell therapy involving permanent gene modification
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic stem cell transplant.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Relapsing MS Cohort

    Biological: CABA-201

  • Experimental
    Progressive MS Cohort

    Biological: CABA-201

Interventions

  • BiologicalCABA-201

    Single intravenous infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide

06

What researchers measure

Primary outcomes

  1. Primary (Part A: Dose Escalation) incidence and severity of adverse events

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal result of an investigation), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. The term AE is used to include both serious and non-serious AEs.

    Time frame: Up to 28 days after CABA-201 infusion

  2. Primary (Part B: Dose Expansion) incidence of and severity of adverse events in order to confirm the dose(s) of CABA-201

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal result of an investigation), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. The term AE is used to include both serious and non-serious AEs.

    Time frame: Up to 28 days after CABA-201 infusion

Secondary outcomes

  1. Part A and Part B: To evaluate the incidence and severity of adverse events

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal result of an investigation), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. The term AE is used to include both serious and non-serious AEs.

    Time frame: Up to 156 weeks after CABA-201 infusion

  2. Part A and Part B: To characterize the pharmacodynamics (PD)

    Levels of B cells in the blood

    Time frame: Up to 156 weeks after CABA-201 infusion

  3. Part A and Part B: To characterize the pharmacokinetics (PK)

    Levels of CABA-201-positive T cells in the blood

    Time frame: Up to 156 weeks after CABA-201 infusion

  4. Part A and Part B: To evaluate disease related biomarkers

    Levels of MS biomarkers in the blood and CSF

    Time frame: Up to 156 weeks after CABA-201 infusion

  5. Part A and Part B: To evaluate the effects of CABA-201 on MS disease activity as measured by Magnetic Resonance Imaging (MRI)

    Incidence of accumulated MS-related lesions

    Time frame: Up to 156 weeks after CABA-201 infusion

  6. Part A and Part B: The effects of CABA-201 on MS disease activity as measured by EDSS

    The EDSS is a scale for assessing neurologic impairment in MS. Values are from 0 points (normal neurological examination) up to 10 points (death). Higher scores represent increased disability.

    Time frame: Up to 156 weeks after CABA-201 infusion

  7. Part A and Part B: To evaluate the effect of CABA-201 on use of subsequent MS-related therapy

    Proportion of participants who require no subsequent MS-related immunomodulatory therapy

    Time frame: Up to 156 weeks after CABA-201 infusion

  8. Part A and Part B: To evaluate the effect of CABA-201 on patient reported and health outcomes as measured by SF-36 v2

    Change in SF-36 v2

    Time frame: Up to 156 weeks after CABA-201 infusion

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Sep 2028, 27 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2025
First posted
Jun 5, 2025
StartEst.
Jun 2026
Primary completionEst.
Sep 2028
CompletionEst.
Oct 2029
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07006805
Lead sponsor
Cabaletta Bio
Responsible party
Sponsor
First posted
Jun 5, 2025
Start date
Jun 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Oct 2029 (estimated)
Last update
Jun 25, 2026

Study contacts

Medical Monitor
study chair · Cabaletta Bio

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Anti-CD19 CAR-T Cells CABA-201

Start the discussion